OCD FiPS3-Ep6F-6
ESi103-A
General
Cell Line |
|
| hPSCreg name | ESi103-A |
| Cite as: | ESi103-A (RRID:CVCL_A8ID) |
| Alternative name(s) |
OCD FiPS3-Ep6F-6
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 21st September 2023 |
| User feedback | |
Provider |
|
| Generator | Spanish Stem Cell Bank (ES) |
| Owner | Spanish Stem Cell Bank (ES) |
| Distributors | |
| Derivation country | Spain |
External Databases |
|
| Cellosaurus | CVCL_A8ID |
| Wikidata | Q107116602 |
| BioSamples | SAMEA114383869 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 40-44 |
| Ethnicity | Unknown |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA114388822 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Mecanismos genéticos y epigenéticos en el trastorno obsesivo compulsivo refractario: desarrollo y validación de un modelo celular mediante reprogramación. |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | No |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Authorised personnel |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Comité ético de Investigación Clínica del Hospital Universitario Ramón y Cajal |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Comité ético de Investigación Clínica del Hospital Universitario Ramón y Cajal |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
Synonyms
|
| Source cell origin |
A fibroblast of skin.; Skin fibroblasts specialized cells found in the dermis, the middle layer of the skin, where they play critical roles in maintaining skin health and functionality. Characterized by an elongated, spindle-like shape, skin fibroblasts are the principal active cells in the connective tissue of the skin. The primary function of skin fibroblasts is the maintenance and regeneration of the extracellular matrix, which provides structural and nutritional support for other skin cells, particularly keratinocytes and epithelial cells. These cells contribute to the production of collagen, elastin, and glycosaminoglycans - key proteins that maintain the elasticity, strength, and resilience of the skin. Through this function, skin fibroblasts help prevent skin aging and maintain tissue integrity, contributing to the skin's overall health and appearance.
In addition, skin fibroblasts are implicated in the skin's wound healing process. Following injury, fibroblasts migrate to the wound site where they start proliferating and laying down new connective tissue. They play a vital role in the repair, regeneration, and healing of the skin; in the final stages of wound healing, skin fibroblasts help contract the healing tissue to minimize scar formation. Furthermore, recent research highlights their role in the immune response, with some studies indicating that skin fibroblasts can react to, and have a role in dealing with, pathogen invasion.
(This extended description was generated by ChatGPT and reviewed by the CellGuide team, who added references, and by the CL editors, who approved it for inclusion in CL. It may contain information that applies only to some subtypes and species, and so should not be considered definitional.)
|
| Age of donor (at collection) | 40-44 |
| Collected in | 2019 |
| Passage number reprogrammed | 4 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | good morphology and integration and silencing of reprogramming vectors |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
||||||
| O2 Concentration | 21 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ 1
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|||||
| NANOG |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| SSEA-3 |
Yes |
|||||
| SSEA-4 |
Yes |
|||||
| TRA 1-60 |
Yes |
|||||
| TRA 1-81 |
Yes |
Differentiation Potency
In vivo teratoma
In vitro directed differentiation
In vivo teratoma
In vitro directed differentiation
In vivo teratoma
In vitro directed differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.